Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Filters applied:Clear all
3 result(s) found, displaying 1 to 3

  • AusPAR: Tecentriq

    Australian public assessment report (AusPar)
    AusPAR for Tecentriq (atezolizumab) for conversion of provisionally registered indication (for treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)) to full registration (withdrawn).

  • AusPAR: Tecentriq

    Australian public assessment report (AusPar)
    New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

  • AusPAR: Bevacizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Bevacizumab